+321 123 4567
info@test.com
My Account
  • Home
  • News
  • About
    • The ASCENT project
    • Digital Adherence Technologies
    • Our Approach
    • Funding & support
    • Consortium Partners
  • Countries
    • Ethiopia
    • South Africa
    • Tanzania
    • The Philippines
    • Ukraine
  • Technologies
    • Products
    • Market landscape
    • Market Size
    • Platform Workstream
  • Resources
  • Contact
  • connect with us

KNCV ramps up support for the expanded use of digital adherence technology in the Philippines

2 weeks ago
The Phillippines
No Comments

PBSP will expand the use of the smart pillbox for tuberculosis (TB) treatment in the Philippines. To jumpstart the scale-up, KNCV is providing technical support to PBSP.

Read More

Video: How Nugusse from Ethiopia got cured from tuberculosis using the smart pillbox

1 month ago
Ethiopia
No Comments

Nugusse, who rides horse drawn carriages for a living in Ethiopia, successfully completed his tuberculosis (TB) treatment using a digital adherence technology (DAT), provided by the ASCENT project.

Read More

Video: Tsedale from Ethiopia demonstrates the use of the medication label/sleeve for TB treatment

2 months ago
Ethiopia
No Comments

In this video, made in Ethiopia, Tsedale explains the advantages she experienced using a DAT, the medication sleeve/label, in comparison to DOT.

Read More

The smart pillbox carves a path to better tuberculosis management and cure

2 months ago
The Phillippines
No Comments

A first person account on how digital adherence technology can help reinforce medication adherence, in a way that benefits the patient and enhances health system efficiency.

Read More

ASCENT Philippines concludes digital adherence technology implementation activities; DAT scale-up assured in 2023

2 months ago
The Phillippines
No Comments

ASCENT concluded digital adherence technology (DAT) implementation activities in the Philippines. PBSP will expand DAT use nationwide.

Read More

Philippines scales up ASCENT’s implementation of digital technology for tuberculosis treatment

2 months ago
The Phillippines
No Comments

The ASCENT project will phase out in December 2022. The Philippines, however, will expand the use of digital adherence technology across the country in 2023.

Read More

Video: How a digital adherence technology, the medication sleeve/label, helps a small-scale farmer from Tanzania

3 months ago
Tanzania
No Comments

Meet Romana, a small scale farmer from Tanzania. She uses the medication sleeve/label to remind her to take her tuberculosis medication.

Read More

“With the smart pillbox alarm, it is impossible to forget your medication”, a TB patient treated in Ethiopia using DAT

3 months ago
Ethiopia
No Comments

A tuberculosis survivor named Netsanet, a 35-year-old mother of three, explained her experience on the use of digital adherence technology for her treatment.

Read More

ASCENT presents two out of ten top-scoring abstracts at the Union World Conference on Lung Health 2022

3 months ago
ASCENT
No Comments

The ASCENT project is beyond exited to join the Union World Conference 2022 starting tomorrow, and presents several oral abstracts, symposia and e-posters.

Read More

Video from South Africa: a healthcare worker’s perspective on digital adherence technology

3 months ago
South Africa
No Comments

Sello Mavimbela has been a healthcare worker in tuberculosis (TB) management for 28 years, and tells you in this video about his view on digital adherence technology for TB treatment.

Read More

THE ASCENT PROJECT

The ASCENT project helps people affected with TB successfully complete their treatment through the use of digital adherence technologies and data-driven support interventions, utilizing smart pill boxes and other innovations. By generating evidence, establishing a global market and engaging stakeholders, ASCENT aims to make future scale up possible so that these digital innovations can be available to all TB patients worldwide.

Sign up to our newsletter

connect with us

Twitter
Facebook

This project is made possible thanks to
Unitaid funding and support.

Disclaimer – Privacy and Cookie statement

Subscribe to newsletter